Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

Sobral MVS, Rodrigues LK, Barbosa AMP, da Rocha NC, Moulaz IR, Dos Santos JPP, Oliveira BHC, Moreira JLML, Pacagnelli FL, Guida CM

American journal of cardiovascular drugs : drugs, devices, and other interventions5 Feb 2025Cited by 2 (Europe PMC)

PMID39907981DOI10.1007/s40256-025-00721-4PepBankPUB-39907981

Publisher page PubMedAsk about this study

Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanSystematic reviewEfficacy outcome
In patients with HFpEF, pooled studies found semaglutide increased 6-minute walk distance versus placebo (mean difference 16.20).
In plain wordsIn patients with heart failure with preserved ejection fraction, semaglutide increased walking distance more than placebo in pooled studies.
Peptide
Semaglutide
Outcome
Increase6-minute walk distance
Study
n = 1,463
Comparator
Placebo
Outcome group
Exercise and physical function · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
6MWD mean difference
16.2 NA
semaglutide vs placebo
Source sentences
Summary
Compared to placebo, the use of semaglutide was associated with a significant increase in the 6-min walk distance (MD 16.20; 95% CI 10.19-22.21; p 2 = 0%).
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF.
Summary · context
This meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients.
Report a problemFND-3990798101
02HumanSystematic reviewEfficacy outcome
In patients with HFpEF, pooled studies found semaglutide reduced systolic blood pressure versus placebo (mean difference -2.22).
In plain wordsIn patients with heart failure with preserved ejection fraction, semaglutide lowered systolic blood pressure more than placebo in pooled studies.
Peptide
Semaglutide
Outcome
DecreaseSystolic blood pressure
Study
n = 1,463
Comparator
Placebo
Outcome group
Blood pressure · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
SBP mean difference
−2.22 NA
semaglutide vs placebo
Source sentences
Summary
Additionally, reductions were observed in systolic blood pressure (MD -2.22; 95% CI -3.60 to -0.83; p 2 = 0%), C-reactive protein level (MD 0.59; 95% CI 0.49-0.70; p 2 = 51%), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels (MD 0.81;…
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF.
Summary · context
This meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients.
Report a problemFND-3990798102
03HumanSystematic reviewEfficacy outcome
In patients with HFpEF, pooled studies reported reduced CRP with semaglutide versus placebo (mean difference 0.59).
In plain wordsIn patients with heart failure with preserved ejection fraction, semaglutide lowered the inflammation marker CRP versus placebo in pooled studies.
Peptide
Semaglutide
Outcome
DecreaseC-reactive protein
Study
n = 1,463
Comparator
Placebo
Outcome group
Inflammation markers · Immune and inflammation
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
CRP mean difference
0.59 NA
semaglutide vs placebo
Source sentences
Summary
Additionally, reductions were observed in systolic blood pressure (MD -2.22; 95% CI -3.60 to -0.83; p 2 = 0%), C-reactive protein level (MD 0.59; 95% CI 0.49-0.70; p 2 = 51%), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels (MD 0.81;…
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF.
Summary · context
This meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients.
Report a problemFND-3990798103
04HumanSystematic reviewEfficacy outcome
In patients with HFpEF, pooled studies reported reduced NT-proBNP with semaglutide versus placebo (mean difference 0.81).
In plain wordsIn patients with heart failure with preserved ejection fraction, semaglutide lowered the heart strain marker NT-proBNP versus placebo in pooled studies.
Peptide
Semaglutide
Outcome
DecreaseNT-proBNP
Study
n = 1,463
Comparator
Placebo
Outcome group
Heart function · Cardiovascular
Studied dose
Dose not stated · 52 weeksAs given in this study (human).
Measurements
NT-proBNP mean difference
0.81 NA
semaglutide vs placebo
Source sentences
Summary
Additionally, reductions were observed in systolic blood pressure (MD -2.22; 95% CI -3.60 to -0.83; p 2 = 0%), C-reactive protein level (MD 0.59; 95% CI 0.49-0.70; p 2 = 51%), and N-terminal prohormone of brain natriuretic peptide (NT-proBNP) levels (MD 0.81;…
2 context sentences(design, population, supporting numbers)
Summary · context
We systematically searched EMBASE, PubMed, and Cochrane databases for randomized controlled trials (RCTs) and non-randomized cohorts, from inception to July 2024, comparing semaglutide versus placebo in patients with HFpEF.
Summary · context
This meta-analysis included three studies, two RCTs and one non-randomized cohort, reporting data on 1463 patients.
Report a problemFND-3990798104

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.